Search results for "ship"

showing 10 items of 6731 documents

Pulsatile versus continuous oxytocin infusion for the oxytocin challenge test.

1994

In a prospective study, 140 patients had an oxytocin challenge test with either a continuous or a pulsed infusion (one minute of infusion in every five minutes). Both infusion regimens had similar success rates in terms of uterine contractions (97.1 vs 98.6%). The potency ratio (pulsed versus continuous infusion) was significant at 2.7 (1.27 to 5.2), which means that more uterine activity was induced with each mU of oxytocin with pulsatile than with continuous administration. The total amount of oxytocin required to obtain three good contractions in 10 minutes was about 40% less with pulsed administration than with continuous infusion, but the test took 40 minutes longer with the pulsed tha…

AdultOxytocin challenge testContinuous infusionPulsatile flowOxytocinDrug Administration ScheduleUterine contractionUterine ContractionPregnancyMedicineHumansInfusions IntravenousInfusion PumpsUterine activityDose-Response Relationship Drugbusiness.industryPotency ratioInfant NewbornObstetrics and GynecologyGeneral MedicineDose–response relationshipOxytocinAnesthesiaPulsatile FlowFemalemedicine.symptombusinessmedicine.drugArchives of gynecology and obstetrics
researchProduct

A Novel Loss-of-Function Mutation (N48K) in the PTEN Gene in a Spanish Patient with Cowden Disease

2003

Cowden disease, also known as multiple hamartoma syndrome, is a rare disease inherited in an autosomal dominant pattern, which confers a high risk of developing breast and thyroid carcinomas. Mutations in PTEN, a tumor suppressor gene located on chromosome 10q23, have been identified in patients with Cowden disease. In this work, the direct sequencing of all coding regions of the PTEN gene led us to the identification of N48K, a new germline PTEN missense mutation, in a patient suffering from Cowden disease. The genetic analysis of 200 chromosomes from healthy individuals revealed that the variant was not common in our population. Moreover, by functional analysis we found that the ability o…

AdultPTENcongenital hereditary and neonatal diseases and abnormalitiesTumor suppressor geneDNA Mutational AnalysisMolecular Sequence DataLoss of Heterozygositygenetic analysisDermatologyProtein Serine-Threonine Kinasesmedicine.disease_causeProto-Oncogene MasBiochemistryGenètica molecularfunctional analysisLoss of heterozygosityStructure-Activity RelationshipProto-Oncogene ProteinsmedicineLeukocytesMissense mutationPTENHumansPoint MutationCowden diseaseAmino Acid SequenceMolecular BiologyTumorsGeneticsMutationbiologySequence Homology Amino AcidPoint mutationTumor Suppressor ProteinsPTEN PhosphohydrolaseMultiple hamartoma syndromeCowden syndromeCell Biologymedicine.diseasePhosphoric Monoester HydrolasesN48KSpainbiology.proteinCancer researchFemaleHamartoma Syndrome MultipleProto-Oncogene Proteins c-akt
researchProduct

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population‐bas…

2021

Objective: Investigate all-cause and cause-specific late mortality after childhood acute lymphoblastic leukemia (ALL) in a population-based Nordic cohort. Methods: From the cancer registries of Denmark, Finland, and Sweden, we identified 3765 five-year survivors of ALL, diagnosed before age 20 during 1971–2008. For each survivor, up to five matched comparison subjects were randomly selected from the general population (n = 18,323). Causes of death were classified as relapse related, health related, and external. Late mortality was evaluated by cumulative incidences of death from 5-year survival date. Mortality hazard ratios (HR) were evaluated with Cox proportional models. Results: Among th…

AdultPediatricsmedicine.medical_specialtycause-specific mortalityDenmarkPopulationlong-term follow-upacute lymphoblastic leukemiaDECADESCohort StudiesYoung AdultCancer SurvivorsSurvivorship curvechildhood cancerHumansMedicineCumulative incidenceeducationChildhood Acute Lymphoblastic LeukemiaFinlandSwedeneducation.field_of_studyOvertreatmentbusiness.industryHazard ratioDEATHCancer5-YEAR SURVIVORSHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCANCERConfidence intervalREDUCTIONOncologylate mortalityPediatrics Perinatology and Child HealthCohortFOLLOW-UPbusinesssurvivorshipPediatric Blood & Cancer
researchProduct

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the lit…

2018

This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its treatment we present studies showing a dose–response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes …

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaOsteoporosisMEDLINEAdministration OralCochrane Library03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesDiabetes mellitusHealth careEpidemiologymedicineHumans030212 general & internal medicineIntensive care medicineRandomized Controlled Trials as TopicAsthmaDose-Response Relationship Drugbusiness.industrymedicine.diseaseAsthma030228 respiratory systembusinessEuropean Respiratory Journal
researchProduct

Clinical Recognition and Management of Adult Attention Deficit Hyperactivity Disorder

1996

Adults with attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) are a new phenomenon to many health care providers. While increasing evidence indicates children with ADD/ADHD can have persistent problems into adulthood, the significance and management of these disorders for adults are poorly understood. Studies of adults are confounded by frequent comorbidity with other conditions and by retrospective diagnosis of childhood ADD/ADHD. Research studies of pharmacologic interventions do not indicate a clear pattern of efficacy and safety for any drug class. Pharmacologic treatment of adults with ADD/ADHD is often guided by clinical experience. Efficacy of treat…

AdultReferralbusiness.industryMEDLINEmedicine.diseaseImpulsivitybehavioral disciplines and activitiesComorbidityAntidepressive AgentsDiagnosis DifferentialPsychotherapyInterpersonal relationshipDrug classAttention Deficit Disorder with Hyperactivitymental disordersHealth carePrevalencemedicineHumansAttention deficit hyperactivity disorderCentral Nervous System Stimulantsmedicine.symptombusinessGeneral NursingClinical psychologyThe Nurse Practitioner
researchProduct

A study protocol for applying the co-creating knowledge translation framework to a population health study

2013

Background: Population health research can generate significant outcomes for communities, while Knowledge Translation (KT) aims to expressly maximize the outcomes of knowledge producing activity. Yet the two approaches are seldom explicitly combined as part of the research process. A population health study in Port Lincoln, South Australia offered the opportunity to develop and apply the co-KT Framework to the entire research process. This is a new framework to facilitate knowledge formation collaboratively between researchers and communities throughout a research to intervention implementation process. Design: This study employs a five step framework (the co-KT Framework) that is formulate…

AdultRural PopulationKnowledge managementAdolescentParticipatory action researchHealth InformaticsKnowledge frameworkKnowledge creationKnowledge translationTranslational Research BiomedicalStudy ProtocolYoung Adult03 medical and health sciences0302 clinical medicineNursingKnowledge translationSouth AustraliaHumansMedicine030212 general & internal medicineAction researchChildHealth policyAgedMedicine(all)business.industry030503 health policy & servicesHealth PolicyPopulation healthPublic Health Environmental and Occupational HealthHealth services researchInfantGeneral MedicineMiddle AgedKnowledge baseResearch DesignChild PreschoolPopulation SurveillanceCommunity healthKnowledge translation modelCommunity health0305 other medical sciencebusinessAction researchEngaged scholarshipImplementation Science
researchProduct

Influence of nifedipine on the metabolism of gingival fibroblasts.

1994

Calcium antagonists are the gold standard in the therapy of coronary heart disease and hypertension. The prototype of these drugs is nifedipine which, as well as its therapeutic effects on the cells of the cardiovascular system, also has unpleasant side effects on other organ systems. One side effect can be a missive hyperplasia of the gingiva, the reason for which are unclear. In vitro experiments were designed to elucidate the influence of nifedipine on the growth of human gingival fibroblasts in short and long term (72 hours, 6 weeks) cell culture. The following cellular parameters were determined quantitatively: cell proliferation (cell count, [3H]thymidine incorporation), protein synth…

AdultSide effectNifedipineCell SurvivalCellGingivaPharmacologyBiochemistrychemistry.chemical_compoundNifedipineCyclosporin aLactate dehydrogenasemedicineHumansCells CulturedDose-Response Relationship DrugChemistryCell growthDNAHyperplasiaFibroblastsmedicine.diseaseChromatography Ion Exchangemedicine.anatomical_structureCell cultureProtein BiosynthesisProteoglycansCell Divisionmedicine.drugBiological chemistry Hoppe-Seyler
researchProduct

Beta-adrenergic blocking activity and haemodynamic effects in man of K� 1313, a new beta-adrenergic antagonist

1971

The beta-adrenergic blocking activity and haemodynamic effects of o-[2-hydroxy-3-(isopropylamino)-propoxy]-benzonitril (Ko 1313) have been studied in 22 patients. Antagonism of isoproterenol-induced tachycardia was used as a measure of the beta-adrenergic blocking activity. Ko 1313 1.0 mg had its maximum beta-adrenoceptor blocking effect 5–30 min after intravenous injection. Ko 1313 10.0 mg produced maximum betablockade 1–4 h after oral administration. 1.0 mg Ko 1313 injected intravenously had approximately the same beta-adrenergic blocking effect as 1.0 mg propranolol also given intravenously. After intravenous administration Ko 1313 was 3–4 times as potent as the same dose given orally. A…

AdultTachycardiamedicine.medical_specialtyCardiac outputAdolescentAdrenergic receptorCardiac VolumeAdrenergic beta-AntagonistsAdministration OralBlood Pressure1-PropanolPropranololPharmacologyElectrocardiographyHeart RateOral administrationInternal medicineNitrilesHeart ratemedicineHumansPharmacology (medical)Cardiac OutputPharmacologyBeta-adrenergic blocking agentPropylaminesbusiness.industryHemodynamicsIsoproterenolGeneral MedicineMiddle AgedAmino AlcoholsPropranololDose–response relationshipEndocrinologyInjections IntravenousSympatholyticsVascular Resistancemedicine.symptombusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

A quantitative study of the pancuronium antagonism at the motor endplate in human organophosphorus intoxication

1995

Nine patients with organophosphorus (OP) intoxication developing neuromuscular transmission defects were given pancuronium 1, 2, or 4 mg intravenously (IV). Thirteen patient controls with hypoxic encephalopathy received similar dosages. The responses were monitored electrophysiologically using single and repetitive nerve stimulation (20 and 50 Hz). In OP patients, pancuronium did not alter the amplitude of the single CMAP, whereas its repetitive discharges were reduced. Severe neuromuscular blocks were reversed only partially by pancuronium 4 mg. In less severe blocks, 1 and 2 mg resulted in marked improvement. In the patient controls, pancuronium 4 mg induced a severe neuromuscular block b…

AdultTime FactorsPhysiologymedicine.medical_treatmentNeuromuscular transmissionAction PotentialsElectromyographyMotor EndplateSynaptic TransmissionNeuromuscular junctionCellular and Molecular Neurosciencechemistry.chemical_compoundOrganophosphate PoisoningPhysiology (medical)medicineHumansPancuroniumRepetitive nerve stimulationAntidoteNeuromuscular BlockadeMovement DisordersDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryNeuromuscular DiseasesAcetylcholinesteraseElectric Stimulationmedicine.anatomical_structurechemistryAnesthesiaInjections IntravenousToxicityAcetylcholinesteraseNeurology (clinical)businessMuscle & Nerve
researchProduct

A first-in-human study of PDC31 (prostaglandin F2  receptor inhibitor) in primary dysmenorrhea

2014

What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)?The 1 mg/kg/h dose of PDC31 appears to be safe and potentially effective in reducing intrauterine pressure (IUP) and pain associated with excessive uterine contractility when given as a 3-h infusion in patients with PD.PDC31 has previously been shown to reduce the duration and strength of PGF2α-induced contractions in human uterine myometrial strip models and to delay delivery in animal models of preterm labor.This was a prospective, multi-center, dose-escalating first-in-human Phase I study conducted from March 2011 to June 2012. A total of …

AdultVisual analogue scaleUterusPlaceboDrug Administration ScheduleUterine contractionYoung AdultDysmenorrheaPharmacokineticsInfusion ProceduremedicineHumansProspective StudiesAdverse effectDose-Response Relationship Drugbusiness.industryRehabilitationObstetrics and GynecologyTreatment Outcomemedicine.anatomical_structureReproductive MedicineAnesthesiaPharmacodynamicsFemalemedicine.symptomPeptidesbusinessHuman Reproduction
researchProduct